Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in hepatitis (viral, B) and HIV infection.
- Mechanism
- Curator reviewed
Elvucitabine is a L-cytosine Nucleoside analog Reverse Transcriptase Inhibitor (NRTIs) anti-HIV drug. NRTI's inhibit the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B) and HIV infection.Curator reviewed
- Formula / weight
- C9H10FN3O3 · 227.195 g/mol (avg)
- Code names
- ACH-126,443
Resolves to
HSBKFSPNDWWPSL-VDTYLAMSSA-NSMILESNC1=NC(=O)N(C=C1F)[C@H]1O[C@@H](CO)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Elvucitabine, and which of those have an active Phase 3 trial?